Navigation Links
Ronald DePinho, M.D., selected for prestigious Agilent Technologies Thought Leader Award

HOUSTON Pancreatic cancer is one the deadliest and hardest to treat cancers. In recognition of his leadership of an innovative translational research program targeted at pancreatic cancer, Ronald DePinho, M.D., president of The University of Texas MD Anderson Cancer Center, was selected for the prestigious Agilent Thought Leader Award.

The Thought Leader Award recognizes researchers whose discoveries represent fundamental advances in the life sciences. DePinho, one of only three awardees in 2012, was selected for his research into pancreatic cancer metabolomics. To further promote DePinho's work, the award provides instrumentation and support to examine the metabolic flux that occurs in the earliest stages of the cancer.

Metabolomics analyzes the physiology of the cell, providing a snapshot of cellular energy stores, as well as metabolic precursors and products. Unlocking and targeting the secrets of the cancer metabolism is a powerful therapeutic strategy, as metabolism is a critical cellular process inherent to cancer cell survival.

DePinho's lab recently reported in the journal Cell a study that leverages metabolomic and transcriptome analysis. This work was the first to link a genetic mutation in the Kras gene to both pancreatic cancer initiation and the subsequent manipulation of metabolic pathways that support tumor growth and progression.

Altered cellular metabolism has long been acknowledged as a hallmark of cancer, but until recently technology couldn't identify discrete and targetable metabolic transformations, aberrations unique to cancer cells. Cancer cells have radically different metabolic properties from the tissue of origin. They require more energy and cellular building blocks to support not only rapid growth, but also survival, as they face harsh conditions from cellular assaults.

DePinho's research group, along with scientists from MD Anderson's Institute for Applied Cancer Science (IACS), will employ the Agilent's instrumentation and software provided to uncover in an unbiased manner alterations in metabolic flux that occur in pancreatic cancer. These discoveries may lead to the identification of biomarkers for the early detection of pancreatic cancer and serve as the basis for developing novel drugs. In fact, IACS currently has multiple metabolism-centric drug discovery programs under way, which will be enhanced by the increased capabilities in metabolomics.

"I'm honored to receive this award," says DePinho. "I've had a long-standing focus on pancreatic cancer, as it remains one of the most difficult to treat cancers due to the lack of effective therapeutic strategies. This technology will allow us to rapidly identify new targets that drive its formation, progression and maintenance, which will translate into clinical advances."


Contact: Hilary Graham
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. UT MD Anderson President Ronald DePinho elected to National Academy of Sciences
2. Renowned Cosmetic and Plastic Surgeon, Ronald L. Moy, M.D. to Present at Upcoming AACS Meeting on TriPollar, a Breakthrough in Radio Frequency Technology
3. California Body Care Supports USO Tribute Show at Ronald Reagan Library
4. Edith Mitchell, M.D., FACP, named 2012 recipient of ASCO Humanitarian Award
5. ASH awards Timothy J. Ley, M.D., with 2012 E. Donnall Thomas Lecture and Prize
6. ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
7. ASH honors David Ginsburg, M.D., and Richard Aster, M.D., with 2012 Henry M. Stratton Medal
8. Penn Medicines Daniel J. Rader, M.D., receives AHAs Clinical Research Prize
9. Richard Mayeux, M.D., M.S., elected Fellow of AAAS
10. Corita Grudzen, M.D., named a practice change leader to improve health care for older adults
11. Tripp, D.O, F.A.C.O.O.G., Adelstein, D.O, F.A.C.O.O.G., MacFarlane, M.D., F.A.C.O.G., Vardo, D.O, F.A.C.O.G., & Abisla, A.N.P., Receive InTone Specialist Certification
Post Your Comments:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... celebrating the opening of the Integrative Biosciences Center (IBio), a $93 million facility ... A grand opening celebration will be held at 10:30 a.m. Wednesday, Oct. 14, ...
(Date:10/13/2015)... ... October 14, 2015 , ... The ... of needle-placement technique in radiofrequency ablation for treatment of lumbar facet arthropathy ”. ... in nature, highlights the importance of anatomically correct needle placement technique for lumbar ...
(Date:10/13/2015)... ... October 13, 2015 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... A Commitment to Cure last night at the Mandarin Oriental in New York ...
(Date:10/13/2015)... ... 13, 2015 , ... “Women have 2 questions when they find out they ... second is, “Will I lose my hair?’” , Carly Klein is the Founder of ... medical professionals to develop personalized hair loss treatment plans. With 10 years’ experience in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Though trick-or-treating remains ... confines of their home. Whether it's making fun pre or post trick-or-treat snacks ... Florida Dairy Farmers. , Recipe 1: Green Chile Queso Dip with Sriacha ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , October 14, 2015 ... The Global Nocturia Clinical Trials Review, H2, ... of worldwide Nocturia scenario, top line data ... as information on companies and institutes involved. ... . --> ...
(Date:10/13/2015)... NEW YORK , Oct. 13, 2015 ... been filed against Amicus Therapeutics, Inc. ("Amicus" or the ... action, filed in United States District Court, District of ... of a class consisting of all persons or entities ... October 1, 2015 inclusive (the "Class Period"). This class action ...
(Date:10/13/2015)... 13, 2015  The Alliance for Safe Biologic ... survey of 401 U.S. pharmacists showing strong support for ... for more transparency in labeling. Michael Reilly ... "This survey reinforces what ASBM has been hearing ... it clear that they prefer distinguishable names and more ...
Breaking Medicine Technology: